scholarly journals Investigating the effect of tamsulosin on the measurement of bladder wall thickness and International Prostate Symptom Score in benign prostatic hyperplasia

2013 ◽  
Vol 7 (5-6) ◽  
pp. 317 ◽  
Author(s):  
Kamyar Eghbali ◽  
Mohammad Reza Shayegan ◽  
Sina Kianoush
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Symptom Score ◽  
Wall Thickness ◽  
Bladder Wall ◽  
Specific Antigen ◽  
Digital Rectal Examination ◽  
Prostatic Hyperplasia ◽  
Chi Square ◽  
Bladder Wall Thickness ◽  
International Prostatic Symptom Score

Introduction: According to previous studies, aging, gender, bladder volume and pathological states, such as bladder outflow obstruction, affect bladder wall thickness (BWT). The aim of this study was to evaluate the correlation between BWT and the International Prostatic Symptom Score (IPSS) in patients with benign prostatic hyperplasia (BPH) before and after tamsulosin treatment.Methods: In this study, 60 BPH patients were included. After obtaining informed consent, data were gathered using questionnaires to determine IPSS. After that, prostate-specific antigen was measured and a clinical examination, including a digital rectal examination, was performed for all patients. BWT was determined by transabdominal ultrasound. Finally, all patients were treated with tamsulosin (0.4 mg/day) for 2 months. After completing treatment, the IPSS and BWT were measured again and compared with the initial findings.Results: In total, 44 patients completed treatment. Patients aged 61.7 ± 9.2 years old. The mean ± standard deviation of IPSS and BWT were 14.6 ± 5.0 and 5.36 ± 1.28 mm before treatment, while they significantly (p < 0.0001) decreased to 8.2 ± 4.7 and 4.69 ± 1.23 mm, respectively, after treatment. Chi-square test showed that the decrease in BWT was significantly correlated with the improvement in IPSS (p = 0.002; r = 0.449).Conclusion: After treatment with tamsulosin, patients experienced a reduction in their BWT which was significantly correlated with improvement in their IPSS. We conclude that transabdominal evaluation of BWT could be included in the follow-up assessment in BPH.

scholarly journals Add-on treatment with mirabegron may improve quality of life in patients with benign prostatic hyperplasia complaining of persistent storage symptoms after tamsulosin monotherapy

2020 ◽  
Vol 12 ◽  
pp. 175628722097413
Author(s):  
Tae Wook Kang ◽  
Hyun Chul Chung
Keyword(s):  
Quality Of Life ◽  
Benign Prostatic Hyperplasia ◽  
Combination Therapy ◽  
Symptom Score ◽  
Specific Antigen ◽  
Prostatic Hyperplasia ◽  
International Prostatic Symptom Score ◽  
Bladder Symptom ◽  
Persistent Storage

Background: The aim of this study was to evaluate the change in lower urinary tract symptoms and quality of life (QoL) after combination therapy of solifenacin and mirabegron in patients with benign prostatic hyperplasia presenting with persistent storage symptoms after treatment with tamsulosin. Material & Methods: We evaluated the International Prostatic Symptom Score (IPSS), Overactive Bladder Symptom Score (OABSS), prostate-specific antigen, prostate volume, peak flow rate (Qmax), and post-voided residual volume (PVR) before and after treatment. Patients showing baseline OABSS ⩾3 were included and treated with tamsulosin 0.2 mg as an initial drug for 1 month. After 1 month, add-on treatment with solifenacin 5 mg or mirabegron 50 mg was provided to patients who did not show improvement in OABSS with tamsulosin 0.2 mg. After 2 months, we evaluated changes in OABSS, IPSS, Qmax, and PVR. Results: After combination therapy for 2 months, there were no significant differences between patients receiving add-on treatment with solifenacin and those receiving mirabegron. However, the IPSS QoL score improved in patients treated with mirabegron and tamsulosin more than in those treated with solifenacin and tamsulosin ( p < 0.05). Conclusion: A combination of tamsulosin and mirabegron might improve the QoL of patients presenting with persistent storage symptoms after tamsulosin monotherapy. Better QoL due to mirabegron compared with solifenacin could be associated with fewer adverse effects, such as dry mouth and constipation.

scholarly journals Correlation between bladder wall thickness and IPSS in patients having benign prostatic hyperplasia.

2020 ◽  
Vol 27 (12) ◽  
pp. 2553-2557
Author(s):  
Moin Anwar ◽  
Muhammad Saifullah ◽  
Muhammad Tahir Bashir Malik ◽  
Muhammad Irfan Munir ◽  
Muhammad Akmal ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Wall Thickness ◽  
Bladder Wall ◽  
Previous History ◽  
Cross Sectional Study ◽  
Prostatic Hyperplasia ◽  
Strong Positive Correlation ◽  
Cross Sectional ◽  
Bladder Wall Thickness ◽  
Medical College

Objectives: Our objective was determination of the correlation between mean bladder wall thickness and mean IPSS in BPH diagnosed patients. Study Design: Cross sectional study. Setting: Department of Urology & Renal Transplantation, Punjab Medical College / Allied Hospital, Faisalabad. Period: Six months from 01-04-2016 to 30-09-2016. Material & Methods: Total 70 patients were enrolled for study from outpatient department of Urology, AHF. IPSS was calculated and recorded. Transabdominal ultrasound KUB was done to measure bladder wall thickness. Urine complete examination and culture was done to rule out UTI. Existence of bladder tumor was ruled out by previous history and ultrasonography. The data was collected on a Proforma by myself. Results: Out of 70 enrolled cases, 47.14% (n=33) were aged 50-60 years whereas 52.86% (n=37) were 61-70 years of age. Mean age was calculated as 61.27+5.31 years. Mean Bladder Wall thickness was 3.64+0.72 and IPSS was calculated to be 12.84+2.79 (r0.9056). Correlation between mean bladder wall thickness and mean IPSS in patients having benign prostatic hyperplasia was calculated as significant. Conclusion: In patients suffering from BOO due to BPH, we have found a very strong positive correlation between mean IPSS and mean BWT. However, bigger studies using standardized techniques are required to establish this fact.

Granulomatous prostatitis: A clinico-pathological series of 27 cases

2020 ◽  
pp. 205141582097042
Author(s):  
Pooja Suteri ◽  
Arvind Ahuja ◽  
Achin K Sen ◽  
Hemant Goel ◽  
Minakshi Bhardwaj ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Histopathological Examination ◽  
Specific Antigen ◽  
Transrectal Ultrasound ◽  
Digital Rectal Examination ◽  
Prostatic Hyperplasia ◽  
Definitive Diagnosis ◽  
Patient Records ◽  
Age Range ◽  
Granulomatous Prostatitis

Objectives: This study aimed to assess the incidence and discern the histomorphological spectrum of granulomatous prostatitis. Methods: A retrospective analysis of histopathological records of 1773 prostatic specimens received in the pathology department was done over a period of seven years. All histologically proven cases of granulomatous prostatitis were retrieved, the relevant clinical data were collected from patient records and the lesions were categorized accordingly. Results: Out of 1773 cases, 27 cases of granulomatous prostatitis were identified. The age range of these patients was between 50 and 89 years. Among the patients, non-specific granulomatous prostatitis (NSGP) was the most common followed by tubercular prostatitis, post-surgical prostatitis and xanthogranulomatous prostatitis. Three cases of post-surgical prostatitis were associated with malignancy. Serum prostate-specific antigen (PSA) levels ranged between 0.8 and 20.94 ng/mL (median 10.78 ng/mL). The diagnosis was made by histopathological examination of transrectal ultrasound (TRUS)-guided core biopsies, Trucut biopsies, transuretheral resection of prostate chips, prostatectomy and cystoprostatectomy specimens. Conclusion: In the present study, the incidence of granulomatous prostatitis was 1.5%. The patients usually present as hard nodules on digital rectal examination along with raised serum PSA levels. Carcinoma or benign prostatic hyperplasia was kept as a clinical diagnosis in these cases. Since the diagnosis of granulomatous prostatitis is made on histopathological examination only, meticulous histomorphological assessment is therefore required to reach a definitive diagnosis of granulomatous prostatitis.

Prescriber Monitoring for Benign Prostatic Hyperplasia Within a Family Medicine Clinic

2012 ◽  
Vol 25 (2) ◽  
pp. 164-168
Author(s):  
Justin J. Sherman ◽  
Ron W. Welch ◽  
T. Matthew Hill ◽  
Corey McEwen
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Family Medicine ◽  
Adverse Effects ◽  
Chart Review ◽  
Specific Antigen ◽  
Digital Rectal Examination ◽  
Prostatic Hyperplasia ◽  
Symptom Index ◽  
Alpha Blockers ◽  
Medicine Clinic

Purpose: The purpose of this study was to compare prescriber monitoring for safety and efficacy of medication classes used to treat benign prostatic hyperplasia (BPH). Methods: This was a retrospective chart review of patients diagnosed with BPH who were prescribed medications within a family medicine clinic between January 2008 and August 2010. Patients were divided into those receiving nonselective and uroselective alpha-blockers, 5-alpha reductase inhibitors (5-ARIs), and combination therapy. A chart review was performed with regard to predetermined criteria to monitor how efficacy and adverse effects were assessed by providers in the clinic. Results: A general genitourinary assessment was documented most frequently for patients receiving 5-ARIs and least frequently in patients receiving nonselective alpha-blockers. A digital rectal examination was documented in 11% of patients. Prostate-specific antigen concentrations were assessed evenly across all medication classes and documented in 47% of eligible patients.  However, the American Urological Association Symptom Index and quality-of-life questions were not performed on any patients, and assessments of adverse effects were not documented. Conclusion:  Although prescribers in a family medicine clinic recorded a general genitourinary assessment for patients receiving BPH medications, a more standardized approach is needed.

Sign in / Sign up

Export Citation Format

Share Document